CIK: 0001389933
Total reported value
$439.6M
Reporting period: 2026-03-31 · Number of holdings: 83
DAFNA Capital Management LLC disclosed 83 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $439.6M and a quarterly turnover rate of 29.7%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "D"
DAFNA Capital Management LLC's disclosed holdings carry a Herfindahl concentration index of 0.043 — mathematically equivalent to about 23 equally-sized positions, well below its 83 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes vary widely across the portfolio (a coefficient of variation of 1.61), with a handful of outsized bets alongside many smaller positions.
No strong tilt toward either adding to existing winners or initiating outsized new positions was observed in the latest reported quarter.
Sector classification currently covers about 22% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add DAWNGBX
-2.1% $11.7M
Trim CYTK
-41.4% -$9.2M
Add NKTR
+120.2% $8.7M
Add CMPS
+198.2% $7.8M
Trim AXGN
-47.6% -$7.3M
Add RVMD
-3.9% $8.3M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | RVMD | Revolution Medicines INC | Stock-Healthcare | 12.85% | +1.67% | -3.94% | |
| 2 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 9.25% | — | -5.35% | |
| 3 | STXS | Stereotaxis INC | Stock-Other | 5.73% | -1.58% | — | |
| 4 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 4.77% | +2.61% | -2.07% | |
| 5 | ATRC | Atricure INC | Stock-Other | 3.88% | -1.61% | — | |
| 6 | IDYA | Ideaya Biosciences INC | Stock-Other | 3.61% | -0.46% | -5.92% | |
| 7 | XENE | Xenon Pharmaceuticals INC | Stock-Other | 3.32% | +0.32% | -12.91% | |
| 8 | CYTK | Cytokinetics INC | Stock-Healthcare | 3.26% | -2.22% | -41.38% | |
| 9 | CMPS | Compass Pathways PLC | Stock-Other | 3.04% | +1.74% | +198.24% | |
| 10 | NKTR | Nektar Therapeutics | Stock-Other | 2.70% | +1.96% | +120.24% | |
| 11 | IBB | Ishares Biotechnology ETF | ETF-Tech | 2.39% | -0.28% | -8.81% | |
| 12 | RCUS | Arcus Biosciences INC | Stock-Other | 2.18% | -0.21% | +2.90% | |
| 13 | NBIX | Neurocrine Biosciences INC | Stock-Healthcare | 2.12% | -0.21% | — | |
| 14 | LRMR | Larimar Therapeutics INC | Stock-Other | 2.08% | +1.25% | +116.06% | |
| 15 | BCAX | Bicara Therapeutics INC | Stock-Other | 1.91% | +0.89% | +61.22% | |
| 16 | AXGN | Axogen INC | Stock-Other | 1.88% | -1.74% | -47.58% | |
| 17 | BHVN | Biohaven Ltd. | Stock-Other | 1.63% | -0.87% | -11.46% | |
| 18 | TNDM | Tandem Diabetes Care INC | Stock-Other | 1.55% | -0.26% | — | |
| 19 | DNLI | Denali Therapeutics INC | Stock-Other | 1.39% | +0.17% | — | |
| 20 | ASND 2.25 04-01-28 | Ascendis Pharma A/s | Stock-Other | 1.35% | — | — | |
| 21 | IPSC | Century Therapeutics INC | Stock-Other | 1.25% | +0.60% | -12.86% | |
| 22 | DXCM | Dexcom INC | Stock-Healthcare | 1.23% | — | -2.27% | |
| 23 | 4XC1 | Kalvista Pharmaceuticals INC | Stock-Other | 1.22% | — | -25.06% | |
| 24 | ASND | Ascendis Pharma A/S | Stock-Other | 1.21% | -0.19% | -17.75% | |
| 25 | MBX | Mbx Biosciences INC | Stock-Other | 1.19% | — | +6.17% | |
| 26 | INGN | Inogen INC | Stock-Other | 1.19% | — | +2.19% | |
| 27 | SNDX | Syndax Pharmaceuticals INC | Stock-Other | 1.16% | -0.20% | -21.77% | |
| 28 | ALKS | Alkermes plc | Stock-Healthcare | 1.12% | +0.27% | +7.09% | |
| 29 | STOK | Stoke Therapeutics INC | Stock-Other | 0.97% | +0.17% | +20.21% | |
| 30 | BCRX | Biocryst Pharmaceuticals INC | Stock-Other | 0.93% | +0.17% | +2.87% | |
| 31 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 0.89% | — | — | |
| 32 | IMVT | Immunovant INC | Stock-Other | 0.85% | — | — | |
| 33 | EWTX | Edgewise Therapeutics INC | Stock-Other | 0.80% | — | -29.74% | |
| 34 | MPLT | Maplight Therapeutics INC | Stock-Other | 0.79% | +0.20% | +18.95% | |
| 35 | ALLO | Allogene Therapeutics INC | Stock-Other | 0.76% | +0.32% | -0.72% | |
| 36 | PRCT | Procept Biorobotics CORP | Stock-Other | 0.68% | -0.20% | — | |
| 37 | ALGN | Align Technology INC | Stock-Healthcare | 0.58% | — | -6.25% | |
| 38 | ✓ | Proqr Thrapeutics N V | Stock-Other | 0.58% | -0.16% | — | |
| 39 | HELP | Cybin INC | Stock-Other | 0.54% | -0.32% | +9.53% | |
| 40 | RAPP | Rapport Therapeutics INC | Stock-Other | 0.53% | — | — | |
| 41 | PODD | Insulet CORP | Stock-Healthcare | 0.52% | — | +58.22% | |
| 42 | GPCR | Structure Therapeutics INC | Stock-Other | 0.51% | — | +25.68% | |
| 43 | ✓ | Immatics NV | Stock-Other | 0.51% | — | -13.51% | |
| 44 | CLDX | Celldex Therapeutics INC | Stock-Other | 0.49% | — | — | |
| 45 | LXEO | Lexeo Therapeutics INC | Stock-Other | 0.49% | -0.30% | +10.62% | |
| 46 | ALEC | Alector INC | Stock-Other | 0.44% | +0.11% | — | |
| 47 | VKTX | Viking Therapeutics INC | Stock-Healthcare | 0.44% | — | — | |
| 48 | KURA | Kura Oncology INC | Stock-Other | 0.44% | — | — | |
| 49 | PROF | Profound Medical CORP | Stock-Other | 0.39% | -0.13% | -7.95% | |
| 50 | FULC | Fulcrum Therapeutics INC | Stock-Other | 0.36% | +0.36% | NEW |
Performance for Q3 2026
+16.4%
Performance Last 4 Quarters
+86.3%
Based on 80% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 83 | $439.6M | 30 | |
| 2025-12-31 | 77 | $430.5M | 36 | |
| 2025-09-30 | 75 | $404.8M | 41 | |
| 2025-06-30 | 76 | $362.3M | 0 | |
| 2025-03-31 | 83 | $352.7M | 100 | |
| 2024-12-31 | 82 | $393.4M | 0 | |
| 2024-09-30 | 84 | $423.3M | 0 | |
| 2024-06-30 | 83 | $418.6M | 0 | |
| 2024-03-31 | 72 | $439.3M | 0 | |
| 2023-12-31 | 76 | $417.3M | 0 | |
| 2023-09-30 | 75 | $321.5M | 0 | |
| 2023-06-30 | 73 | $365.7M | 0 | |
| 2023-03-31 | 72 | $333.5M | 0 | |
| 2022-12-31 | 79 | $355.1M | 0 | |
| 2022-09-30 | 87 | $371.8M | 0 | |
| 2022-06-30 | 90 | $366.9M | 0 | |
| 2022-03-31 | 94 | $383.8M | 0 | |
| 2021-12-31 | 87 | $397.7M | 0 | |
| 2021-09-30 | 80 | $376.9M | 0 | |
| 2021-06-30 | 84 | $478.2M | 33 | |
| 2021-03-31 | 89 | $421.5M | 43 | |
| 2020-12-31 | 74 | $336.1M | 48 | |
| 2020-09-30 | 80 | $307.6M | 44 | |
| 2020-06-30 | 87 | $346.5M | 51 | |
| 2020-03-31 | 80 | $239.6M | 48 | |
| 2019-12-31 | 81 | $291.3M | 44 | |
| 2019-09-30 | 89 | $265.9M | 32 | |
| 2019-06-30 | 87 | $266.0M | 36 | |
| 2019-03-31 | 79 | $231.8M | 58 | |
| 2018-12-31 | 83 | $201.1M | 34 | |
| 2018-09-30 | 75 | $243.5M | 24 | |
| 2018-06-30 | 75 | $213.6M | 32 | |
| 2018-03-31 | 75 | $205.6M | 44 | |
| 2017-12-31 | 72 | $185.7M | 36 | |
| 2017-09-30 | 73 | $161.1M | 39 | |
| 2017-06-30 | 75 | $140.1M | 39 | |
| 2017-03-31 | 72 | $118.2M | 47 | |
| 2016-12-31 | 66 | $113.8M | 57 | |
| 2016-09-30 | 75 | $143.6M | 58 | |
| 2016-06-30 | 95 | $126.2M | 52 | |
| 2016-03-31 | 94 | $115.9M | 58 | |
| 2015-12-31 | 78 | $112.2M | 46 | |
| 2015-09-30 | 88 | $100.8M | 42 | |
| 2015-06-30 | 76 | $118.2M | 71 | |
| 2015-03-31 | 71 | $130.2M | 48 | |
| 2014-12-31 | 62 | $126.4M | 46 | |
| 2014-09-30 | 59 | $99.1M | 48 | |
| 2014-06-30 | 49 | $105.5M | 32 | |
| 2014-03-31 | 46 | $116.4M | 40 | |
| 2013-12-31 | 47 | $97.2M | 45 | |
| 2013-09-30 | 52 | $91.5M | 53 | |
| 2013-06-30 | 44 | $68.3M | 0 |
DAFNA Capital Management LLC's most significant position changes for 2026-03-31: Sold out: Astria Therapeutics INC (CATBUSD); New buy: Fulcrum Therapeutics INC (FULC); New buy: Orthopediatrics CORP (KIDS); New buy: Cytomx Therapeutics INC (CTMX); New buy: Maze Therapeutics INC (MAZE).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | DAWNGBX | Day One Biopharmaceuticals I | +2.6% | -2.07% | Trim |
| 2 | NKTR | Nektar Therapeutics | +2% | +120.24% | Add |
| 3 | CMPS | Compass Pathways PLC | +1.7% | +198.24% | Add |
| 4 | RVMD | Revolution Medicines INC | +1.7% | -3.94% | Trim |
| 5 | LRMR | Larimar Therapeutics INC | +1.3% | +116.06% | Add |
| 6 | BCAX | Bicara Therapeutics INC | +0.9% | +61.22% | Add |
| 7 | IPSC | Century Therapeutics INC | +0.6% | -12.86% | Trim |
| 8 | XENE | Xenon Pharmaceuticals INC | +0.3% | -12.91% | Trim |
| 9 | ALLO | Allogene Therapeutics INC | +0.3% | -0.72% | Trim |
| 10 | ALKS | Alkermes plc | +0.3% | +7.09% | Add |
| 11 | MPLT | Maplight Therapeutics INC | +0.2% | +18.95% | Add |
| 12 | RARE | Ultragenyx Pharmaceutical In | +0.2% | +281.88% | Add |
| 13 | DNLI | Denali Therapeutics INC | +0.2% | — | Unchanged |
| 14 | BCRX | Biocryst Pharmaceuticals INC | +0.2% | +2.87% | Add |
| 15 | STOK | Stoke Therapeutics INC | +0.2% | +20.21% | Add |
| 16 | NGNE | Neurogene INC | +0.1% | +102.46% | Add |
| 17 | ALEC | Alector INC | +0.1% | — | Unchanged |
| 18 | PROF | Profound Medical CORP | -0.1% | -7.95% | Trim |
| 19 | ✓ | Mediwound LTD | -0.1% | -16.91% | Trim |
| 20 | VRCA | Verrica Pharmaceuticals INC | -0.2% | -11.38% | Trim |
| 21 | ✓ | Proqr Thrapeutics N V | -0.2% | — | Unchanged |
| 22 | ANNX | Annexon INC | -0.2% | -56.82% | Trim |
| 23 | ASND | Ascendis Pharma A/S | -0.2% | -17.75% | Trim |
| 24 | TELA | Tela Bio INC | -0.2% | — | Unchanged |
| 25 | PRCT | Procept Biorobotics CORP | -0.2% | — | Unchanged |
| 26 | SNDX | Syndax Pharmaceuticals INC | -0.2% | -21.77% | Trim |
| 27 | AQST | Aquestive Therapeutics INC | -0.2% | -2.00% | Trim |
| 28 | NBIX | Neurocrine Biosciences INC | -0.2% | — | Unchanged |
| 29 | RCUS | Arcus Biosciences INC | -0.2% | +2.90% | Add |
| 30 | SPRY | Ars Pharmaceuticals INC | -0.3% | -26.72% | Trim |
| 31 | TNDM | Tandem Diabetes Care INC | -0.3% | — | Unchanged |
| 32 | IBB | Ishares Biotechnology ETF | -0.3% | -8.81% | Trim |
| 33 | LXEO | Lexeo Therapeutics INC | -0.3% | +10.62% | Add |
| 34 | HELP | Cybin INC | -0.3% | +9.53% | Add |
| 35 | IDYA | Ideaya Biosciences INC | -0.5% | -5.92% | Trim |
| 36 | BHVN | Biohaven Ltd. | -0.9% | -11.46% | Trim |
| 37 | STXS | Stereotaxis INC | -1.6% | — | Unchanged |
| 38 | ATRC | Atricure INC | -1.6% | — | Unchanged |
| 39 | AXGN | Axogen INC | -1.7% | -47.58% | Trim |
| 40 | CYTK | Cytokinetics INC | -2.2% | -41.38% | Trim |
| 41 | CATBUSD | Astria Therapeutics INC | — | EXIT | Sold out |
| 42 | FULC | Fulcrum Therapeutics INC | — | NEW | New buy |
| 43 | KIDS | Orthopediatrics CORP | — | NEW | New buy |
| 44 | CTMX | Cytomx Therapeutics INC | — | NEW | New buy |
| 45 | MAZE | Maze Therapeutics INC | — | NEW | New buy |
| 46 | SCYXEUR | Scynexis INC | — | NEW | New buy |
| 47 | ERAS | Erasca INC | — | EXIT | Sold out |
| 48 | ZBIO | Zenas Biopharma INC | — | NEW | New buy |
| 49 | NAMS | NewAmsterdam Pharma Company N.V. | — | NEW | New buy |
| 50 | PLRX | Pliant Therapeutics INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-14 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-14 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-15 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-14 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-14 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-14 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-15 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-14 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-14 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-15 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-16 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-14 | 13F-HR | View on EDGAR |
| 2021-09-30 | 2021-11-15 | 13F-HR | View on EDGAR |
| 2021-06-30 | 2021-08-16 | 13F-HR | View on EDGAR |
| 2021-03-31 | 2021-05-17 | 13F-HR | View on EDGAR |
| 2020-12-31 | 2021-02-16 | 13F-HR | View on EDGAR |
| 2020-09-30 | 2020-11-16 | 13F-HR | View on EDGAR |
| 2020-06-30 | 2020-08-14 | 13F-HR | View on EDGAR |
| 2020-03-31 | 2020-05-15 | 13F-HR | View on EDGAR |
| 2019-12-31 | 2020-02-14 | 13F-HR | View on EDGAR |
| 2019-09-30 | 2019-11-14 | 13F-HR | View on EDGAR |
| 2019-06-30 | 2019-08-14 | 13F-HR | View on EDGAR |
| 2019-03-31 | 2019-05-15 | 13F-HR | View on EDGAR |
| 2018-12-31 | 2019-02-14 | 13F-HR | View on EDGAR |
| 2018-09-30 | 2018-11-14 | 13F-HR | View on EDGAR |
| 2018-06-30 | 2018-08-13 | 13F-HR | View on EDGAR |
| 2018-03-31 | 2018-05-15 | 13F-HR | View on EDGAR |
| 2017-12-31 | 2018-02-14 | 13F-HR | View on EDGAR |
| 2017-09-30 | 2017-11-14 | 13F-HR | View on EDGAR |
| 2017-06-30 | 2017-08-14 | 13F-HR | View on EDGAR |
| 2017-03-31 | 2017-05-15 | 13F-HR | View on EDGAR |
| 2016-12-31 | 2017-02-14 | 13F-HR | View on EDGAR |
| 2016-09-30 | 2016-11-14 | 13F-HR | View on EDGAR |
| 2016-06-30 | 2016-08-15 | 13F-HR | View on EDGAR |
| 2016-03-31 | 2016-05-16 | 13F-HR | View on EDGAR |
| 2015-12-31 | 2016-02-12 | 13F-HR | View on EDGAR |
| 2015-09-30 | 2015-11-13 | 13F-HR | View on EDGAR |
| 2015-06-30 | 2015-08-14 | 13F-HR | View on EDGAR |
| 2015-03-31 | 2015-05-15 | 13F-HR | View on EDGAR |
| 2014-12-31 | 2015-02-17 | 13F-HR | View on EDGAR |
| 2014-09-30 | 2014-11-14 | 13F-HR | View on EDGAR |
| 2014-06-30 | 2014-08-14 | 13F-HR | View on EDGAR |
| 2014-03-31 | 2014-05-15 | 13F-HR | View on EDGAR |
| 2013-12-31 | 2014-02-14 | 13F-HR | View on EDGAR |
| 2013-09-30 | 2013-11-14 | 13F-HR | View on EDGAR |
| 2013-06-30 | 2013-08-14 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001672666
Total reported value
$439.3M
3 stks
2025-12-31
Stale — no recent filing
AUM within 0.1% of this institution
CIK 0000938077
Total reported value
$439.9M
180 stks
2026-03-31
AUM within 0.1% of this institution
CIK 0002046157
Total reported value
$439.9M
162 stks
2026-03-31
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0000096223
Total reported value
$14.6B
1,692 stks
2026-03-31
1 of the top 5 holdings overlap, including Ss Spdr S&p Biotech ETF
CIK 0000860645
Total reported value
$83.5M
21 stks
2026-03-31
1 of the top 5 holdings overlap, including Ss Spdr S&p Biotech ETF
CIK 0000909661
Total reported value
$17.5B
172 stks
2026-03-31
1 of the top 5 holdings overlap, including Revolution Medicines INC